UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
GENOMICS & PRECISION MEDICINE

QIAGEN

Q

QIAGEN

Visit Website

About QIAGEN

QIAGEN pioneered the column-based nucleic acid purification method that became the global standard for molecular biology, and today its sample-to-insight technologies are used in more than 500,000 laboratories across 160 countries. Founded in 1984 in Düsseldorf, Germany, and listed on both the Nasdaq and the Frankfurt Stock Exchange under the ticker QGEN, the company occupies a singular position in life sciences: it sits at the very front of the analytical workflow, ensuring that the biological sample reaching any downstream instrument is clean, consistent, and ready for meaningful results.

Sample Technologies & Molecular Diagnostics

The company's portfolio spans consumables, automated instruments, and bioinformatics, unified by the principle that sample quality determines everything that follows. Its QIAamp, RNeasy, and DNeasy product families are reference standards in research and clinical settings alike. The QIAsymphony and QIAcube platforms automate extraction workflows from research benches through to hospital laboratories, reducing hands-on time and variability. In molecular diagnostics, QIAGEN markets CE-marked and FDA-cleared assays covering infectious disease detection, oncology companion diagnostics, and human identification, with the QIAstat-Dx syndromic testing system enabling rapid, near-patient panel testing for respiratory and gastrointestinal pathogens.

Bioinformatics & Precision Medicine

Through its QIAGEN Digital Insights division, the company provides bioinformatics software that connects raw sequencing output to clinical and biological interpretation. Ingenuity Pathway Analysis and the CLC Genomics Workbench are widely used in both pharmaceutical research and translational medicine. The QCI Interpret platform supports variant classification for oncology and rare-disease workflows, positioning QIAGEN as a partner across the continuum from discovery research to regulated diagnostics. Therapy areas served include oncology, infectious disease, immunology, and forensics, with a growing presence in liquid biopsy and companion diagnostic development for pharmaceutical partners.

Headquartered in Venlo, Netherlands, with operational hubs in Hilden, Germany, and Germantown, Maryland, QIAGEN employs approximately 6,000 people worldwide and generates revenues in excess of two billion US dollars annually. The company serves customers in pharmaceuticals, biotechnology, clinical diagnostics, applied testing, and academic research.

Further information is available at qiagen.com.

Similar Companies

More in Genomics & Precision Medicine

T

Thermo Fisher Scientific

Thermo Fisher Scientific is the world's largest supplier of scientific instruments, reagents, consumables, software and services, with a mission to enable customers to make the world healthier, cleaner and safer. Founded in 2006 through the merger of Thermo Electron and Fisher Scientific, the company traces its operational roots back more than a century and today employs roughly 125,000 people across more than 50 countries. Life Sciences & Bioproduction Platforms The company's Life Sciences Solutions segment is a cornerstone of global drug discovery and development. Its portfolio spans cell biology reagents, gene expression tools, next-generation sequencing platforms, proteomics instruments and the widely adopted Invitrogen, Applied Biosystems and Gibco product families. Thermo Fisher's bioproduction business supplies single-use bioreactors, cell culture media and downstream purification technology to manufacturers producing biologics, cell therapies and vaccines at commercial scale. Pharma Services & Analytical Instruments Through its Pharma Services Group, Thermo Fisher operates as one of the largest contract development and manufacturing organisations globally, offering clinical trial logistics, drug substance manufacturing, fill-finish, packaging and cold-chain distribution. The analytical instruments segment serves quality control, environmental testing and materials characterisation, with mass spectrometers, electron microscopes and chromatography systems deployed throughout pharmaceutical, food safety and forensic laboratories. Listed on the New York Stock Exchange under the ticker TMO, Thermo Fisher consistently ranks among the highest-revenue companies in life science tools. Its Unity Lab Services division provides outsourced laboratory management and equipment maintenance, reducing operational burden for hospital, academic and industrial customers alike. The company has been an active acquirer, with notable transactions including the purchases of Life Technologies, Patheon, PPD and Binding Site broadening its reach across diagnostics, clinical research and speciality immunology. Headquartered in Waltham, Massachusetts, the company serves pharmaceutical and biotech clients, academic researchers, hospitals and government agencies across every inhabited continent. Further information is available at thermofisher.com.

View profile
A

Alkahest

Mining what it describes as the deepest layers of plasma knowledge, Alkahest combines artificial intelligence, multiomics analysis and real-world data with deep plasma protein expertise to drive drug discovery. A subsidiary of Grifols, the California-based research company focuses on identifying and developing transformative therapies derived from the science of plasma. The scientific foundation underlying Alkahest's pipeline rests on the premise that the plasma proteome is in constant flux, influencing human biology in ways that can both sustain and undermine health. According to the company, alterations in plasma protein concentration and conformation are linked to multiple drivers of disease, with changes appearing years before clinical diagnosis. This positions plasma proteins as potential early biomarkers capable of informing prediction, diagnosis and treatment. A significant competitive asset is access to Grifols' plasma repository, which the company describes as one of the world's largest collections, comprising more than 100 million plasma samples gathered over nearly 15 years. The dataset spans thousands of disease states and is linked to real-world health records. Alkahest applies advanced analytical and integrative multiomics capabilities to this resource to build an evolving picture of the protein network and its relationship to human ageing and disease. The company's work sits at the intersection of plasma biology, data science and therapeutic development, representing a scientifically grounded approach to conditions where conventional small-molecule or antibody strategies have faced limitations. Further information is available at alkahest.com.

View profile
T

Tempus AI

Tempus AI pioneered the application of artificial intelligence to clinical and molecular data at scale, building one of the world's largest libraries of multimodal health data to help physicians make more informed treatment decisions at the point of care. Founded in 2015 by Eric Lefkofsky in Chicago, the company grew rapidly by partnering with health systems, academic medical centres, and pharmaceutical companies across the United States and internationally. Its core platform ingests genomic sequencing results, clinical records, imaging, and pathology data, then applies machine learning models to surface insights relevant to individual patient care and broader population-level research. Tempus operates two closely linked business lines. Its clinical arm provides genomic sequencing and molecular diagnostics services directly to oncologists and other specialists, returning structured, AI-annotated reports alongside raw sequence data. Its life science arm licenses de-identified, longitudinal datasets and analytical tools to pharmaceutical and biotechnology companies conducting real-world evidence studies, biomarker discovery, and clinical trial design and recruitment optimisation. Oncology has historically been the company's primary focus, where the intersection of genomic complexity and data volume makes AI-driven decision support particularly valuable. Tempus has progressively expanded into cardiology, neuropsychiatry, radiology, and infectious disease, broadening the scope of its data assets and the range of clinical partners it serves. The company listed on the Nasdaq exchange under the ticker symbol TEM in June 2024, marking one of the more prominent healthcare technology initial public offerings of that year. Its platform, known as the Tempus Intelligence Network, connects data contributors and data consumers in a structure designed to grow in analytical value as participation increases. Further information is available at tempus.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy